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ABSTRACT
Objective: Paclitaxel is one of the most effective anticancer agents. It is used as a chemotherapy agent for a spectrum of cancer types. However, 
paclitaxel resistance is one of the foremost problems for chemotherapy. Most importantly, an emergence of paclitaxel resistance due to mutation 
(F270V) in β-tubulin has been extremely deliberated in recent years. With the rise of paclitaxel-resistant mutation in β-tubulin, there is a need to add 
a novel inhibitor from natural source, as they have less chance of getting resistance additionally less side effects. Keeping this in mind, we have utilized 
experimental and in silico approaches to isolate the potent inhibitor for β-tubulin target protein.
Methods: We have extracted phytocompounds from Cassia fistula plant, and the structures were recognized with the help of gas chromatography-
mass spectrometry technique. Subsequently, oral bioavailability and toxicity analysis were executed for the extracted compounds by employing 
MOLINSPIRATION and OSIRIS program, respectively. Furthermore, docking analysis was performed using YASARA algorithm. In addition, bioactivity 
analysis for the screened compounds was performed using prediction of activity spectra for substances program.
Results: The results from our analysis clearly depict that HOP-22(29)-EN-3.BETA.-OL could be a promising inhibitor for the treatment of cancer and 
provide direction for future research. Further in vitro and in vivo exploration is also required to identify whether HOP-22(29)-EN-3.BETA.-OL have 
anticancer effect or not.
Conclusion: The combination of computational approach and experimental analysis provides an easy approach to identify novel candidate for the 
target protein β-tubulin.
Keywords: Phytochemicals, Gas chromatography mass spectrometry, Bioavailability, Molecular docking, Prediction of activity spectra for substances 
prediction.
INTRODUCTION
About 3% of cancers among women associate for ovarian cancer, 
it causes high death rates than any other types of cancer in the 
reproductive system of female. Ovarian cancers inherent danger 
to women’s health is connected by the bottom line that it is notably 
very complicated to detect. The major cause of high death rates 
for the diseases immediately needs to be dealt with through safe 
and effective new treatments. Ovarian cancer has come out as one 
of the most widespread malignancy affecting women in India. The 
chemotherapeutic agents particularly paclitaxel is one of the widely 
used drugs for the treatment against a variety of tumors including 
breast, ovarian, lung and head, and neck cancers [1,2]. It targets 
β-subunit (i.e., β-tubulin) of microtubules. This β-subunit makes 
heterodimer with the α-subunit to build microtubules. Paclitaxel binds 
to the β-subunit part and makes the microtubule stabilized against 
depolymerization. This, in turn, leads to the decrease in the dynamic 
behavior of microtubules and leads to a mitotic arrest in cell cycle 
and apoptosis process [3]. Even though, paclitaxel is a widely used 
chemotherapeutic agent, the advancement of resistance has limited 
its use in clinical trials as other chemotherapeutic drugs [4]. Most 
importantly, resistance due mutation is the major cause of paclitaxel 
resistance in the β-subunit of microtubules. Of note, mutation at 
position 270 in β-tubulin (phenylalanine to valine) leads to paclitaxel 
resistance at higher levels in the patients. Thus, there is a keen 
interest in the discovery of potent β-tubulin inhibitors which may 
help to overcome paclitaxel resistance in the treatment of ovarian 
cancer. These problems could be addressed definitely by the help of 
computational approaches. Most importantly, plants as a source of 
bioactive components with anticancer properties can be served as 
chemotherapeutic agents for the treatment of cancer. Moreover, 60% 
of drugs available in market are derived from plant sources such as 
paclitaxel [5,6]. Keeping this in mind, the present study targets to 
identify potent inhibitors from the plant Cassia fistula [7-9] to target 
β-tubulin for the treatment of ovarian cancer. We hope our study will 
be valuable in the designing of new anticancer agents for the treatment 
of ovarian cancer in near future.
METHODS
Collection of plant leaves
C. fistula plant leaves were collected from the nursery at VIT University, 
Vellore, Tamil Nadu, India.
Washing, drying and powdering of plant leaves
The collected leaves were then washed under a running tap to remove 
any dirt or unwanted substances. The leaves were then dried under a 
shaded area at room temperature for few days until the moisture was 
removed. The leaves were then crushed and powdered for use in the 
extraction process. The powdered leaves were then further filtered 
using an infuser to obtain a fine powder.
Plant extract preparation
C. fistula powder obtained was then dissolved in four different solvents: 
Ethanol (polar), Methanol (polar), diethyl ether (mid-polar), and 
chloroform (non-polar). The ratio of the extraction solution being one 
part leaf powder to three parts of the solvent (1:3). The prepared mixture 
was kept for a period of 72 hrs at a temperature of 60-65°C during 
which it is stirred after every 3 hrs. The extracts obtained from each 
solvent were filtered using Whatman filter paper. The filtrate obtained 
was then subjected to a drying process using Petri plates and stored in 
room temperature for 48 hrs for the complete removal of solvent [10]. 
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Further gas chromatography-mass spectrometry (GC-MS) [11] analysis 
was performed using 0.50 µg of dried extract sample.
GC-MS analysis of phytochemical compounds
GC-MS analysis is the most preferable technique for analyzing 
the chemical compounds in the plant extract. It helps in the 
identification [12] of structures. Furthermore, it provides 
the information like name, molecular weight (MW), and structure of 
the compounds on interpretation by mass spectrum [13]. 10 mg of 
the extract is used for the GC-MS analysis. Perkin Elmer GC-MS (Model 
PerkinElmer Clarus 600, USA) equipped with VF-5 MS fused silica 
capillary column was employed for the GC-MS analysis of the extracts. 
GC-MS spectroscopic detection, an electron ionization system with 
ionization energy of 70 electron volt was used. Mass transfer line and 
injector temperatures were set at 250°C. Helium gas was used as a 
carrier gas at a constant flow rate of 1 mL per minute [14-16]. The oven 
temperature was kept at 60°C for 2 minutes then increased to 300°C 
for 6 minutes at the rate of 10°C per minute. The same samples were 
injected in split mode as 10:1 [10].
Identification of phytocompounds
National Institute Standard and Technology (NIST) was used to 
interpret the results of mass spectrum. It is a database which consists of 
more than 62,000 patterns. The spectrum of the unidentified substance 
was compared with the known fragments stored in the library of NIST. 
The retention time, MW, name, structure, and concentration (%) of the 
substance analyzed were taken into account [17]. Of note, the results 
will be obtained in the form of chromatogram which contains numerous 
peaks which have a repertoire of phytocompounds.
Data set for in silico analysis
The β-tubulin structure used in our analysis was obtained from the 
Protein Data Bank (PDB). 1TVK [18] is the PDB code which corresponds 
to β-tubulin. The mutant (F270V) structure was generated using Swiss-
PDB viewer [19]. Paclitaxel was used as reference drug for our study. 
The structures of the phytocompounds were obtained from the result 
of GCMS, Wiley9 library analysis. For instance, a total of 29 compounds 
were examined for their inhibiting activity against β-tubulin. The 
SMILES notations for these compounds were retrieved from PubChem 
(NCBI) [20] and submitted to CORINA for deducing the 3D structure of 
compounds [21].
Oral bioavailability and toxicity analysis
Bioavailability and permeability are two important molecular 
properties. They are always associated with various molecular 
descriptors such as logP (partition coefficient), MW, hydrogen bond 
acceptor, and donor counts are also important in a molecule [22]. These 
all molecular properties were used in framing “Lipinki’s Rule of Five 
(LROF)” [23]. According to this the molecules with good membrane 
permeability have MW ≤500, calculated octanol–water partition 
coefficient, logP ≤5, hydrogen bond donors ≤5, acceptors ≤10, and van 
der Waals bumps polar surface area <120 Å 2 [24]. As a result, LROF 
was employed to check the bioavailability (ADME) of the compounds. 
In the study, molecular properties of all the compounds were calculated 
using MOLINSPIRATION program [25]. In addition to this the screening 
was also carried out by restricting the number of violations to a 
maximum of two. Subsequently, toxicity analysis was done to discover 
an effective drug, high-quality compounds which may need to be more 
drug-like than generally acknowledged. And to attain this, it is very 
important to eliminate the compounds with poor pharmacokinetics 
and toxicity in early stages of drug discovery. These biochemical 
properties were, therefore, estimated utilizing OSIRIS program [26] 
for the filtered set of compounds. The OSIRIS program calculates 
mutagenicity, tumorogenicity, irritating effects, and reproductive effects 
which may be used to evaluate the potent inhibitor compound and 
to meet the requirements for a drug. Of note, the physiochemical and 
pharmacokinetics properties may be used to evaluate the compounds 
potential to qualify as a drug candidate. Thus, the compounds fulfilling 
this criterion were further subjected to docking studies.
Molecular docking analysis of phytocompounds
Molecular Docking study was performed to understand the binding 
affinity of compounds with the native and mutant (F270V) type 
β-tubulin protein. AutodockVina [27] algorithm incorporated in 
YASARA software package [28] was used to execute molecular docking 
studies. The difference between the sum of potential and solvation 
energies of the separated compounds and the sum of potential and 
solvation energies of the complex in the YAMBER3 force field was 
utilized to calculate the energy. For instance, more positive energy 
value implies higher binding affinity and less positive energy means 
lower binding affinity. The best 10 clusters score were generated for 
both the native and mutant type complexes. The best confirmation of 
native and mutant β-tubulin complex was selected among 10 clusters 
for further analysis. Moreover, anticancer activity analysis was done for 
the compounds by employing CDRUG program.
Anti-cancer activity analysis of the compounds: CDRUG
Screening of millions and millions of compounds for anticancer activity 
is a very tough, expensive and time taking task. A fast and user-friendly 
server known as CDRUG is described for the prediction of anticancer 
efficiency of various chemicals. In this study, we have employed 
CDRUG to cross-check whether the extracted bioactives from the 
plant poses anti-cancerous property or not [29] CDRUG employs a 
novel molecular description technique (relative frequency-weighted 
fingerprint) to execute the fingerprints of the compound. Of note, the 
similarity between the query and the active compound was measured 
which in turn results in the form of hybrid score. Finally, it estimates 
p value (confidence level) which helps in predicting whether the 
query compound(s) have or do not have anti-cancerous activity [29]. 
Therefore, p value of compounds which shows higher binding energies 
was calculated by employing CDRUG. The p value cutoff (p<0.01) and 
H-score value>1.0 was taken into consideration [30] for the analysis. 
Moreover, the output page of the CDRUG shows the result based on 
color range, i.e., highly possible, possible and less possible results 
are colored by green, black and gray, respectively. The compounds 
falling under these criteria may have anticancer activity. Further, 
the compounds were evaluated for the biological activity using PASS 
prediction.
Prediction of activity spectra for substances (PASS)
Prediction of anticancer activity of the compounds extracted 
from C. fistula was done with the help of PASS [31] program. It is 
a computer-based program used for the prediction of different 
types of pharmacological activities of the substances [31] including 
phytocompounds. The prediction by PASS is based on structural 
activity relationship analysis of the training set containing more than 
205,000 compounds exhibiting more than 3750 kinds of biological 
activities. The predicted activity spectrum of a compound is estimated 
as probable activity (Pa) and probable inactivity [32]. If Pa is more than 
0.7 then the substance is very likely to exhibit the activity in experiment 
and the substance may be known pharmaceutical agent, if Pa is less 
than 0.5, then the substance is very unlikely to exhibit the activity in 
experiment, but the presence will be confirmed by the experiment and 
if Pa is less than 0.5 and more than 0.7, the substance is likely to exhibit 




The GC-MS analysis of phytocompounds in the ethanol, methanol, 
diethyl ether, and chloroform leaf extract of C. fistula explored the 
presence of various bioactive components. The identification of the 
phytocompounds was confirmed based on the molecular formula 
and its structure. The results are presented in Table 1. The results of 
GC-MS show that C. fistula contains 29 bioactive compounds which 
are extracted using different solvent in our study. Further, these 
29 compounds were considered for ADME and toxicity analysis.
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Bioavailability and toxicity assessment
A total of 29 bioactives extracted from C. fistula alongside paclitaxel as 
reference drug were considered in our study. The preliminary screening 
of the compounds was accomplished on the basis of two descriptors 
such as pharmacokinetics and toxicity. The data corresponds to 
the paclitaxel were set as the threshold value for screening the 
lead molecules in all the categories. At first, the pharmacokinetics 
property of the leads was examined using LROF with the help of 
molinspiration program. The output results of molinspiration program 
were presented in Table 2. It is clear from the Table 2 that paclitaxel 
showed 2 violations to the LROF. Further, the numbers of violations of 
the lead compounds resulted from the molinspiration program were 
mapped with the number of violations of paclitaxel for the criterion 
of screening. For instance, the results from our Table 2 indicate that 
5 compounds showed 2 violations in the bioavailability analysis 
and another 14 compounds showed 1 violation to the LROF. Of note, 
11 more compounds from our data set showed zero violation to the 
LROF. Accordingly, 30 compounds from our dataset were chosen for 
further analysis. Subsequently, the toxicity of the screened compounds 
was examined using OSIRIS program. The results are shown in Table 3. 
The results, from our study, indicate that 19 compounds from our 
dataset show no mutagenicity, no tumorigenicity, no reproductive 
effect, and no irritant properties in our data set of 30 molecules. 
However, 11 compounds from the list of 30 compounds show toxicity 
risk when run through the OSIRIS program. Therefore, molecular 
docking analysis was initiated for the compounds.
Molecular docking studies
Docking studies were executed to understand the binding efficiency 
of the compounds derived from the plant C. fistula with the protein 
β-tubulin. We have considered 29 compounds and paclitaxel for 
the docking study. The docked ligand complexes were analyzed 
based on binding energy. The results indicate that compound HOP-
22(29)-EN-3.BETA.-OL has better binding energy both with native 
and mutant type β-tubulin in compare to other compounds and also 
in compare to the paclitaxel. The results are shown in Table 4. Of the 
29 compounds, 3 compounds (Urs-12-En-28-Oic Acid, 3-Hydroxy-, 
Methyl Ester, (3.Beta.), HOP-22(29)-EN-3.BETA.-OL, and Lupeol show 
the best binding energy over paclitaxel. The binding free energies of 
the native and mutant types of β-tubulin paclitaxel complex were 
8.75 and 7.51 kcal/mol, respectively; on the other hand, HOP-22(29)-
EN-3.BETA.-OL shows the binding energy of 9.22 and 9.44 kcal/mol. 
The binding energy indicates that the efficiency of HOP-22(29)-EN-3.
BETA.-OL is competent in compare to paclitaxel with mutant protein. 
Thus, HOP-22(29)-EN-3.BETA.-OL can be a potent molecule to 
overwhelm with drug resistance problem in the treatment of ovarian 
cancer. Subsequently, we have examined compounds for analyzing the 
anticancer activity by employing CDRUG server.
Inferring anticancer potential of the extracted bioactives
The anti-cancer activity of the compounds with higher binding energy 
was evaluated using CDRUG. To infer the compound to be a potential 
candidate for the treatment of ovarian cancer, we have first filtered 
the compounds based on its binding affinity with the target protein 
β-tubulin and we found 3 (HOP-22(29)-EN-3.BETA.-OL; Urs-12-En-28-
Oic Acid, 3-Hydroxy-, Methyl Ester, (3.Beta.) and Lupeol) compounds 
showing higher affinity to bind with the target protein. Then, we 
predicted the anticancer activity of these compounds alongside 
paclitaxel. The results are displayed in Fig. 1. The results clearly depict 
that the compound HOP-22(29)-EN-3.BETA.-OL have anticancer activity 
and also higher binding energy in compare to other compounds and 
paclitaxel. The compounds are found to be in comparable zone on the 
basis of H-score (H-score not>1) p value and Color code. Therefore, we 
have examined the compound for its biological activity to pick up the 
Table 1: List of phytocompounds extracted from the leaves of Cassia fistula
Serial 
number
Compounds extracted Ethanol Methanol Chloroform Diethyl 
ether




3 3,7,11,15tetramethyl2hexadecen-1-ol + + +
4 2R-acetoxymethyl-1,3,3-trimethyl-4t-(3-methyl-2-buten-1-yl)-
1t-cyclohexanol
+ + + +
5 Alpha.-linolenic acid, trimethylsilyl ester + +
6 Dl-.alpha.-tocopherol + + +
7 22,23-dibromostigmasterol acetate + +
8 Tritetracontane +
9 n-hexadecanoic acid + +
10 n-decanoic acid +
11 Urs-12-en-28-oic acid, 3-hydroxy-, methyl ester, (3.beta.) +
12 16-Heptadecenal + +
13 Benzeneethanamine + +
14 (s)-(+)-1-Cyclohexylethylamine +
15 Tetratetracontane + + +
16 Pentadecanal + +




19 3-o-methyl-d-glucose + +
20 Octacosane + +
21 7-hexadecyne +
22 13-Tetradece-11-yn-1-ol + +
23 Lupeol + +
24 Beta.-D-mannopyranoside, methyl + +
25 Dichloromethane + + +
26 Di-n-decylsulfone +
27 HOP-22 (29)-EN-3.BETA.-OL +
28 Phytol + +
29 Vitamin E + +
+ indicates the presence of particular phytocompound in the extract of respective solvent
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Table 2: Oral bioavailability analysis of the phytocompounds using molinspiration program
Serial 
number
Compounds name miLogP TPSA NAtoms MW nON nOHNH Nviolations Nrotb volume








4.434 46.533 20 282.424 3 1 0 5 298.432
4 Alpha.-linolenic acid, 
trimethylsilyl ester
8.71 26.305 24 350.619 2 0 1 15 386.664
5 Dl-.alpha.-tocopherol 9.043 29.462 31 430 2 1 1 12 474.499
6 22,23-dibromostigmasterol 
acetate
9.244 26.305 35 614.547 2 0 2 8 528.851
7 Tritetracontane 10.731 0 43 605.177 0 0 2 40 734.631
8 n-hexadecanoic acid 7.059 37.299 18 256.43 2 1 1 14 291.422
9 n-decanoic acid 4.027 37.299 12 172.268 2 1 0 8 190.612
10 Urs-12-En-28-Oic Acid, 
3-Hydroxy-, Methyl Ester, 
(3.Beta.)
7.405 46.533 34 470 3 1 1 2 489.017
11 16-heptadecanal 6.034 43.376 21 298.467 3 0 1 16 327.96
12 Benzeneethanamine 3.875 3.238 18 239.362 1 0 0 5 251.789
13 (s)-(+)-1-cyclohexylethylamine 1.807 26.023 9 127.231 1 2 0 1 147.307
14 Tetratetracontane 10.763 0 44 619.204 0 0 2 41 751.433
15 Pentadecanal 7.128 17.071 16 226.404 1 0 1 13 266.603
16 Phytol 6.761 20.228 21 296.539 1 1 1 13 349.376
17 7,8-epoxylanostan-11-ol, 
3-acetoxy




4.746 20.228 16 222.372 1 1 0 3 247.988
19 3-o-methyl-d-glucose −2.245 107.217 13 194.183 6 4 0 6 173.348
20 Vitamin E 9.043 29.462 31 430 2 1 1 12 474.499
21 Octacosane 10.051 0 28 394.772 0 0 1 25 482.604
22 7-hexadecyne 7.826 0 16 222.416 0 0 1 10 269.522
23 13-tetradece-11-yn-1-ol 4.999 20.228 15 208.345 1 1 0 9 238.546
24 Lupeol 8.293 20.228 31 426.729 1 1 1 1 461.604
25 Beta.-D-mannopyranoside, 
methyl
−1.505 99.38 13 194.183 6 4 0 3 169.335
26 Dichloromethane 1.511 0 3 84.933 0 0 0 0 56.508
27 HOP-22 (29)-EN-3.BETA.-OL 8.29 20.23 31 426.73 1 1 1 1 461.60
28 Di-n-decylsulfone 8.50 34.14 23 346.62 2 0 1 18 379.62
29 3,7,11,15tetramethyl2hexadecen-
1-ol
6.76 20.23 21 296.54 1 1 1 13 349.38
30 Paclitaxel 4.945 221.307 62 853.918 15 4 2 14 756.598
Serial 
number
Compounds name Mutagenic Tumorigenic Irritant Reproductive 
effect
1 1-hexyl-2-nitrocyclohexane No No No No
2 2,4,4-trimethyl-3-hydroxymethyl-5a-(3-methyl-but-2-enyl)-
cyclohexene
No No No No
3 3,7,11,15-tetramethyl-2-hexadecen-1-ol No No No No
4 2R-acetoxymethyl-1,3,3-trimethyl-4t-(3-methyl-2-buten-1-
yl)-1t-cyclohexanol
No No No No
5 Alpha.-linolenic acid, trimethylsilyl ester No No Yes No
6 Dl-.alpha.-tocopherol No No No No
7 22,23-dibromostigmasterol acetate Yes Yes Yes No
8 Tritetracontane No No No No
9 n-hexadecanoic acid No Yes Yes No
10 n-decanoic acid Yes No Yes No
11 Urs-12-En-28-Oic Acid, 3-Hydroxy-, Methyl Ester, (3.Beta) No No No No
12 16-heptadecenal Yes No Yes Yes
13 Benzeneethanamine Yes No No No
14 (s)-(+)-1-cyclohexylethylamine No No No No
15 Tetratetracontane No No No No
16 Pentadecanal Yes No Yes Yes
Table 3: Toxicity risks assessment phytocompounds predicted by OSIRIS property explorer
(Contd...)
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pace in identifying potent natural products, by employing computer-
aided program PASS for drug discovery.
Pass prediction analysis for anticancer activity
The biological activity spectrum of the compound HOP-22(29)-EN-3.
BETA.-OL was obtained by online PASS version. The biological activity 
spectra (anticancer) evaluated was found in the criteria. PASS predicted 
probable activity (Pa) of the compound HOP-22(29)-EN-3.BETA.-OL 
for antineoplastic activity is 0.935 and antineoplastic (ovarian cancer) 
activity is 0.736. Therefore, it is likely to be the potential lead molecule 
for the inhibition of β-tubulin. Of note, compound HOP-22(29)-EN-3.
BETA.-OL shows antineoplastic activity for ovarian cancer with the 
Pa>0.7. Hence, HOP-22(29)-EN-3.BETA.-OL is proven to be a potent 
anticancer agent. In future, it may offer an alternative source of drug for 
the treatment of ovarian cancer.
CONCLUSIONS
Here, we report the identification of novel molecule, HOP-22(29)-EN-3.
BETA.-OL, which binds effectively with both the native and mutant 
β-tubulin structures. The results of our study signify that bioavailability 
of HOP-22(29)-EN-3.BETA.-OL is significantly higher than paclitaxel. In 
addition, the compound showed no cytotoxicity in the computational 
analysis. Moreover, the binding energy between HOP-22(29)-EN-3.
BETA.-OL and β-tubulin was found to be significantly higher than 
energies between paclitaxel and other plant bioactives with β-tubulin. 
Serial 
number
Compounds name Mutagenic Tumorigenic Irritant Reproductive 
effect
17 Phytol Yes yes Yes Yes
18 7,8-epoxylanostan-11-ol, 3-acetoxy No No Yes No
19 1,3,3-trimethyl-2-hydroxymethyl-3,3-dimethyl-4-(3-
methylbut-2-enyl)-cyclohexene
No No No No
20 3-o-methyl-d-glucose No No No No
21 Vitamin E No No No No
22 Octacosane No No No No
23 7-hexadecyne No No No No
24 13-tetradece-11-yn-1-ol No No Yes No
25 Lupeol No No No No
26 Beta-D-mannopyranoside, methyl No No No No
27 Dichloromethane Yes Yes Yes Yes
28 Di-n-decylsufone No No No No
29 HOP-22 (29)-EN-3.BETA.-OL No No No No





Compounds name Native binding 
energy (kcal/mol)
Mutant (F270V) binding 
energy (kcal/mol)
1 1-hexyl-2-nitrocyclohexane 5.403 5.607
2 2,4,4-trimethyl-3-hydroxymethyl-5a-(3-methyl-but-2-enyl)-cyclohexene 6.399 5.947
3 2R-acetoxymethyl-1,3,3-trimethyl-4t-(3-methyl-2-buten-1-yl)-1t-cyclohexanol 6.630 6.822
4 Alpha.-linolenic acid, trimethylsilyl ester - -
5 Dl-.alpha.-tocopherol 6.633 5.948
6 22,23-dibromostigmasterol acetate 6.192 6.939
7 Tritetracontane 2.965 2.882
8 n-hexadecanoic acid 5.279 5.339
9 n-decanoic acid 4.806 4.726
10 Urs-12-En-28-Oic Acid, 3-Hydroxy-, Methyl Ester, (3.Beta.) 8.036 9.427
11 16-heptadecanal 5.059 4.574
12 Benzeneethanamine 4.988 5.276
13 (s)-(+)-1-cyclohexylethylamine 5.472 5.182
14 Tetratetracontane 3.119 4.072
15 Pentadecanal 4.746 4.624
16 Phytol 5.125 5.897




19 3-o-methyl-d-glucose 4.595 4.846
20 Vitamin E 6.333 5.948
21 Octacosane 3.952 3.128
22 7-hexadecyne 5.099 5.082
23 13-tetradece-11-yn-1-ol 4.873 4.498
24 Lupeol 8.965 8.139
25 Beta.-D-mannopyranoside, methyl 8.965 5.281
26 Dichloromethane 2.302 2.514
27 HOP-22 (29)-EN-3.BETA.-OL 9.221 9.445
28 Di-n-decylsulfone 4.232 5.173
29 3,7,11,15tetramethyl2hexadecen-1-ol 6.229 6.271
30 Paclitaxel 8.759 7.511
-: Indicates the docking energy is not available
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This docking result also suggests that HOP-22(29)-EN-3.BETA.-OL 
interacts well with the residues of the binding site of β-tubulin even in 
the mutant form. Finally, the data obtained from the CDRUG and PASS 
confirmed that HOP-22(29)-EN-3.BETA.-OL is found to have anticancer 
activity. We believe that the present study will be of great help in 
designing the drugs for cancer treatment. This is the first observation of 
HOP-22(29)-EN-3.BETA.-OL inhibitory action toward the target protein 
β-tubulin and further needs to be justified by the experimental support.
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